What is Mounjaro?
Mounjaro (Tirzepatide) is a first-in-class dual GLP-1 and GIP receptor agonist, meaning it targets two hormone pathways for enhanced weight loss and glucose control.
How Does Mounjaro Work?
By activating both GLP-1 and GIP receptors, Mounjaro enhances:
- Hunger suppression
- Fat metabolism and insulin sensitivity
Who is Eligible for Mounjaro?
- Patients with type 2 diabetes needing blood sugar management
- Being prescribed off-label for weight loss
Weight Loss Potential
- Up to 20-25% body weight loss in some trials
- Faster and more effective than other GLP-1 medications
Side Effects
- Gastrointestinal discomfort (nausea, diarrhea, constipation)
- Fatigue and dizziness
- Pancreatitis risk
Dosage
- Injected once a week, similar to Wegovy